Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti.
HIV
genotypic resistance
second-line therapy
tenofovir disoproxil fumarate
zidovudine
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
26
07
2021
accepted:
11
11
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
14
12
2021
Statut:
epublish
Résumé
We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.
Identifiants
pubmed: 34901303
doi: 10.1093/ofid/ofab559
pii: ofab559
pmc: PMC8661077
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab559Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Lancet HIV. 2017 Aug;4(8):e341-e348
pubmed: 28495562
AIDS. 2021 Jul 15;35(9):1423-1432
pubmed: 33973876
N Engl J Med. 2014 Jul 17;371(3):234-47
pubmed: 25014688
PLoS One. 2019 Jul 29;14(7):e0220159
pubmed: 31356613
Lancet HIV. 2016 Jun;3(6):e247-58
pubmed: 27240787
Lancet Infect Dis. 2019 Mar;19(3):253-264
pubmed: 30732940
N Engl J Med. 2021 Jul 22;385(4):330-341
pubmed: 34289276
Lancet Infect Dis. 2016 May;16(5):565-575
pubmed: 26831472